AI assistant
Sending…
LIGAND PHARMACEUTICALS INC — Director's Dealing 2016
Mar 18, 2016
31289_dirs_2016-03-17_83c6ea07-08e9-46f7-a6c9-97a5abb4109c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2016-03-17
Reporting Person: FOEHR MATTHEW W (President and COO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-03-17 | Common Stock | M | 6400.0 | $9.97 | Acquired | 83062 | Direct |
| 2016-03-17 | Common Stock | S | 6400.0 | $96.7 | Disposed | 76662 | Direct |
| 2016-03-17 | Common Stock | M | 2250.0 | $9.97 | Acquired | 78912 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-03-17 | Employee Stock Option (right to buy) | $9.97 | M | 6400.0 | Disposed | 2021-04-18 | Common Stock (6400) | Direct |
| 2016-03-17 | Employee Stock Option (right to buy) | $9.97 | M | 2250.0 | Disposed | 2021-04-18 | Common Stock (2250) | Direct |
Footnotes
F1: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 04/18/11.
More from LIGAND PHARMACEUTICALS INC
Proxy Solicitation & Information Statement
2026
May 18
M&A Activity
2026
May 18
Interim / Quarterly Report
2026
May 8
Earnings Release
2026
May 7
Major Shareholding Notification
2026
May 1
Major Shareholding Notification
2026
May 1
Regulatory Filings
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 27
M&A Activity
2026
Apr 27
Annual Report
2026
Apr 21